• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

    1/5/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email

    IRVING, Texas, Jan. 5, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference, which will be held January 12-15, 2026, in San Francisco, California.

    Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)

    Caris will present and participate in a Q&A session on Monday, January 12 at 1:30 PM PT. Live and replay webcasts will be available on the Investor Relations section of Caris' website at CarisLifeSciences.com.

    About Caris Life Sciences

    Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. 

    Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition.  Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. 

    Caris Life Sciences Media:

    Corporate Communications

    [email protected]

    214.294.5606

    Investor Relations: 

    [email protected] 

    917.689.3511

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302651930.html

    SOURCE Caris Life Sciences

    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    7/14/2025$33.00Outperform
    Evercore ISI
    7/14/2025$32.00Buy
    TD Cowen
    7/14/2025$38.00Buy
    BTIG Research
    7/14/2025$34.00Buy
    Citigroup
    More analyst ratings

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Castleman Peter M exercised 2,500 shares at a strike of $18.60, increasing direct ownership by 16% to 18,629 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    1/13/26 6:37:09 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Power Luke Thomas exercised 62,250 shares at a strike of $2.44 and sold $1,654,461 worth of shares (62,250 units at $26.58) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    12/12/25 7:39:15 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Brille Brian J gifted 1,300 shares, decreasing direct ownership by 0.80% to 161,128 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    12/12/25 6:22:53 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CAI
    SEC Filings

    View All

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan

    IRVING, Texas, Jan. 28, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Nature's npj Breast Cancer journal titled, "Mechanisms of Resistance to Trastuzumab Deruxtecan in Breast Cancer Elucidated by Multiomic Molecular Profiling." Utilizing large-scale real-world clinico-genomic data and Caris's comprehensive multiomic profiling, Caris scientists uncovered clinically relevant mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. This study explains why patient responses vary and reveals how resistance can evolve over time.

    1/28/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results

    Full year revenue growth of approximately 94% driven by strong performance  in molecular profiling services IRVING, Texas, Jan. 12, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Fourth quarter 2025 preliminary unaudited financial results For the three-month period ended December 31, 2025, as compared to the same period of 2024: Total revenue of approximatel

    1/12/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Caris Life Sciences with a new price target

    Canaccord Genuity initiated coverage of Caris Life Sciences with a rating of Hold and set a new price target of $28.00

    12/2/25 8:24:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    BofA Securities initiated coverage on Caris Life Sciences with a new price target

    BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00

    7/14/25 8:49:47 AM ET
    $CAI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Caris Life Sciences with a new price target

    Analyst initiated coverage of Caris Life Sciences with a rating of Overweight and set a new price target of $31.00

    7/14/25 8:49:26 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Caris Life Sciences Inc.

    SCHEDULE 13G - Caris Life Sciences, Inc. (0002019410) (Subject)

    2/5/26 1:20:38 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    1/12/26 9:00:24 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Caris Life Sciences Inc.

    10-Q - Caris Life Sciences, Inc. (0002019410) (Filer)

    11/5/25 5:01:37 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

    IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will

    10/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025

    IRVING, Texas, July 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report second quarter 2025 financial results on Tuesday, August 12, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Tuesday, August 12, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/hfsyg967 A replay of the webcast will be a

    7/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care